24.69

0.52% -0.13

Pre-market: 24.76 0.07 +0.28%

Catalyst Pharmaceuticals Inc (CPRX)

Overview News Price History Option Chain Financials Why CPRX Down? Discussions Forecast

Catalyst Pharmaceuticals Inc stock is traded at $24.69, with a volume of 616.05K. It is down -0.52% in the last 24 hours and up +3.39% over the past month. Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

Previous Close:

$24.82

Open:

$24.54

24h Volume:

616.05K

Relative Volume:

0.52

Market Cap:

$3.02B

Revenue:

$588.99M

Net Income/Loss:

$214.33M

P/E Ratio:

14.66

EPS:

1.6844

Net Cash Flow:

$208.61M

1W Performance:

+1.81%

1M Performance:

+3.39%

6M Performance:

+18.47%

1Y Performance:

+0.94%

1-Day Range:

$24.38

$24.79

1-Week Range:

$23.05

$25.14

52-Week Range:

$19.05

$26.58

Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile

Name

Catalyst Pharmaceuticals Inc

Sector

Healthcare (1116)

Industry

Biotechnology (624)

Phone

(305) 529-2522

Address

355 ALHAMBRA CIRCLE, CORAL GABLES

Employee

182

Twitter

@CatalystForRare

Next Earnings Date

2024-11-06

Latest SEC Filings

CPRX's Discussions on Twitter

Compare CPRX vs VRTX, REGN, ARGX, ALNY, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CPRX Catalyst Pharmaceuticals Inc	24.69	3.02B	588.99M	214.33M	208.61M	1.6844
VRTX Vertex Pharmaceuticals Inc	438.71	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	761.85	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	746.42	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	318.85	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	162.43	35.01B	606.42M	-1.28B	-997.58M	-6.403

Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-04-25	Initiated	Robert W. Baird	Outperform
Nov-18-24	Initiated	Stephens	Overweight
Mar-14-24	Initiated	Citigroup	Buy
Mar-07-24	Initiated	BofA Securities	Buy
Dec-21-23	Initiated	Oppenheimer	Outperform
Aug-24-22	Downgrade	ROTH Capital	Buy → Neutral
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-07-18	Resumed	Piper Jaffray	Overweight
Oct-05-16	Upgrade	Piper Jaffray	Neutral → Overweight
Apr-26-16	Downgrade	Piper Jaffray	Overweight → Neutral
Sep-30-14	Reiterated	ROTH Capital	Buy
Sep-16-14	Reiterated	ROTH Capital	Buy
Sep-15-14	Reiterated	H.C. Wainwright	Buy
Oct-21-13	Reiterated	Aegis Capital	Buy
Sep-24-13	Initiated	Maxim Group	Buy
Sep-06-13	Reiterated	Aegis Capital	Buy
Apr-18-13	Initiated	Aegis Capital	Buy
Aug-27-12	Upgrade	Rodman & Renshaw	Mkt Perform → Mkt Outperform
Oct-01-09	Upgrade	Merriman	Sell → Neutral
May-29-09	Downgrade	Hapoalim	Neutral → Underperform
May-29-09	Downgrade	Merriman Curhan Ford	Buy → Sell
Dec-15-08	Initiated	Merriman Curhan Ford	Buy
Nov-28-07	Initiated	Rodman & Renshaw	Mkt Outperform
Jan-31-07	Initiated	Stifel Nicolaus	Buy
Jan-05-07	Initiated	First Albany	Buy

View All

Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News

Apr 05, 2026